Please assess the completion status of the following clinical trial:

Trial Title: Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with alopecia areata by either:~  * A board-certified dermatologist, OR~ * Dermatology Nurse Practitioner, OR~ * Skin punch biopsy~* Patient has at least 2 alopecic patches each measuring at least 2 cm2 and are...~  * Located on contralateral body sites OR~ * Within the same body site but separated by ≥ 1 cm~* Patient is a candidate for intralesional triamcinolone.~* Patient able to give informed assent under IRB approval procedures when appropriate.~* At least one parent or guardian is able to provide informed consent.~Exclusion Criteria:~* Patient has alopecia totalis, alopecia universalis, or alopecia areata with ophiasis pattern.~* Known allergy or hypersensitivity to triamcinolone acetonide~* Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study.~* Patient is unable/unwilling to provide informed assent when applicable.~* Known medical diagnosis or use of a medication that alters pain response at time of injection.~* Active infection at site designated for injection.~* If currently being treated for alopecia areata, the current treatment regimen has been started within less than 4 weeks of screening.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- MedJet Device (Type: EXPERIMENTAL): The Med-Jet-MBX needle-free injector (Med-Jet) is a novel, needle-free drug-delivery system, which we believe may be a solution to the pain and fear associated with needles. It uses regulated compressed air as a power source to accelerate an injectable fluid through a 0.005 orifice (6x smaller than a 30G needle) to penetrate the skin and deliver medication to a specific anatomical region (MedJet) The drug-delivery device is highly configurable allowing adjustable depth and volume parameters (MedJet). In addition, the high-performance design allows for triggering multiple injection sites rapidly which is practical when needing to treat large surface areas (MedJet).

Based on this trial design, predict the completion outcome and termination type (if applicable).